Finance

Lists
RVTY:NYSE
Revvity Inc
158,07 USD
+1,32%
(+2,06) 1D
21-окт., 11:22:52 GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RVTY...
Open
154,44 USD
High
159,48 USD
Low
152,71 USD
Mkt. cap
17,41 млд
Avg. vol.
2,08 млн
Volume
419,78 миң
52-wk high
159,48 USD
52-wk low
152,71 USD
Beta
1,06
Shares outstanding
111,59 млн
No. of employees
11 миң
Open
154,44 USD
High
159,48 USD
Low
152,71 USD
Mkt. cap
17,41 млд
Avg. vol.
2,08 млн
Volume
419,78 миң
52-wk high
159,48 USD
52-wk low
152,71 USD
Beta
1,06
Shares outstanding
111,59 млн
No. of employees
11 миң
News stories
From web sources and news partners
Profile
Revvity, Inc. is a multinational company headquartered in Waltham, Massachusetts, USA, in the life sciences and diagnostics business that is focused on selling to the pharmaceutical and biotechnology industries, especially in relation to approaches making use of new cell therapy or gene therapy developments. Its origins lie with the long-existing company PerkinElmer, which has been in a variety of business lines. In 2022, a split of PerkinElmer resulted in one part, comprising its applied, food and enterprise services businesses, being sold to the private equity firm New Mountain Capital for $2.45 billion and thus no longer being public but keeping the PerkinElmer name. The other part, comprising the life sciences and diagnostics businesses, remained public but required a new name, which in 2023 was announced as Revvity, Inc. From the perspective of Revvity, the goal of creating a separate company was that its businesses might show greater profit margins and more in the way of growth potential. An associated goal was to have more financial flexibility moving forward. On May 16, 2023, the PerkinElmer stock symbol PKI was replaced by the new symbol RVTY. Wikipedia
About Revvity Inc
CEOPrahlad Singh
Employees11 миң
Founded1947
HeadquartersУолтем, Массачусетс, Америка Кошмо Штаттары
SectorHealth care
Analyst ratings
Based on 14 analysts giving stock ratings to RVTY in the past 3 months
Buy
Buy
4
Hold
10
Sell
0
12-month forecast
Based on 14 Wall Street analysts offering 12 month price targets for RVTY in the last 3 months.
Highest
Current 158,07 USD
175,00 USD (+10,71%)
Average
141,75 USD (-10,32%)
Lowest
110,00 USD (-30,41%)
Analyst
Recommendation
Action
Price target
Projected
Date
Eve Burstein
Bernstein
Hold
Reiterated
120,00 USD
-24,1%
10/19/2026
Casey Woodring
J.P. Morgan
Hold
Maintained
155,00 USD
-1,9%
10/16/2026
Daniel Brennan
TD Cowen
Buy
Maintained
175,00 USD
+10,7%
10/13/2026
Lu Li
Bank of America Securities
Hold
Maintained
165,00 USD
+4,4%
10/09/2026
Michael Ryskin
Bank of America Securities
Hold
Maintained
165,00 USD
+4,4%
10/09/2026
Luke Sergott
Barclays
Hold
Maintained
160,00 USD
+1,2%
10/07/2026
Matt Larew
William Blair
Buy
Initiated
-
-
10/05/2026
Evie Koslosky
Goldman Sachs
Hold
Maintained
140,00 USD
-11,4%
09/20/2026
Unknown Analyst
CFRA
Hold
Downgraded
-
-
09/18/2026
Unknown Analyst
UBS
Hold
Initiated
140,00 USD
-11,4%
09/08/2026
Doug Schenkel
UBS
Hold
Downgraded
140,00 USD
-11,4%
09/09/2026
Paul Knight
KeyBanc
Buy
Maintained
165,00 USD
+4,4%
09/04/2026
Unknown Analyst
KeyBanc
Buy
Maintained
165,00 USD
+4,4%
09/04/2026
Dan Leonard
RBC Capital
Hold
Initiated
135,00 USD
-14,6%
09/01/2026
Vijay Kumar
Evercore ISI
Buy
Maintained
126,00 USD
-20,3%
08/05/2026
Evan Stampler
Wells Fargo
Hold
Maintained
110,00 USD
-30,4%
08/05/2026
Unknown Analyst
Wells Fargo
Hold
Maintained
110,00 USD
-30,4%
08/05/2026
Daniel Arias
Stifel Nicolaus
Hold
Reiterated
110,00 USD
-30,4%
08/05/2026
Puneet Souda
Leerink Partners
Buy
Reiterated
-
-
07/17/2026
Michael Polark
Wolfe Research
Hold
Initiated
-
-
06/01/2026
Unknown Analyst
Guggenheim
Hold
Reiterated
-
-
05/11/2026
Catherine Ramsey Schulte
Robert W. Baird
Buy
Maintained
117,00 USD
-26%
05/04/2026
Unknown Analyst
Goldman Sachs
Hold
Maintained
95,00 USD
-39,9%
04/14/2026
Jack Meehan
Nephron
Hold
Upgraded
90,00 USD
-43,1%
03/26/2026
Brandon Couillard
Wells Fargo
Hold
Maintained
110,00 USD
-30,4%
02/03/2026
Tycho Peterson
Jefferies
Hold
Maintained
105,00 USD
-33,6%
02/02/2026
Next call 13 күндөн кийин
3-ноя., шейш., 14:30
Fiscal period
Q3 2026
- / 1,30 USD
Revenue / Est. (USD)
- / 694,74 млн
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance: upcoming earnings
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
2025-ж. сен.
2025-ж. дек.
2026-ж. апр.
2026-ж. июл.
Revenue
698,95 млн
772,06 млн
711,12 млн
729,69 млн
Cost of goods sold
324,34 млн
350,40 млн
323,46 млн
312,82 млн
Cost of revenue
324,34 млн
350,40 млн
323,46 млн
312,82 млн
Research and development expenses
50,80 млн
58,18 млн
57,89 млн
48,97 млн
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
227,44 млн
208,55 млн
241,91 млн
243,46 млн
Operating expense
278,23 млн
266,73 млн
299,80 млн
292,43 млн
Total operating expenses
602,58 млн
617,12 млн
623,26 млн
605,25 млн
Operating income
96,37 млн
154,93 млн
87,86 млн
124,44 млн
Other non operating income
-
-
-
-
EBT including unusual items
55,68 млн
91,56 млн
49,99 млн
63,53 млн
EBT excluding unusual items
76,49 млн
133,38 млн
65,92 млн
105,36 млн
Income tax expense
8,46 млн
-4,21 млн
9,10 млн
10,05 млн
Effective tax rate
15,20%
-4,60%
18,20%
15,82%
Other operating expenses
-
-
-
-
Net income
46,65 млн
98,36 млн
40,72 млн
51,82 млн
Net profit margin
6,67%
12,74%
5,73%
7,10%
Earnings per share
1,18
1,70
1,06
1,41
Interest and investment income
6,92 млн
5,75 млн
6,30 млн
5,26 млн
Interest expense
-22,77 млн
-23,51 млн
-24,72 млн
-22,99 млн
Net interest expenses
-15,85 млн
-17,76 млн
-18,41 млн
-17,73 млн
Depreciation and amortization charges
-
-
-
-
EBITDA
198,43 млн
258,01 млн
192,91 млн
226,47 млн
Gain or loss from assets sale
-
-
-5,07 млн
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
Google колдонмолору